Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) earlier this quarter.

"This is a significant milestone for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered by Pharmasset scientists" stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We continue to see nucleos(t)ide inhibitors as having the potential to be the cornerstone of future HCV treatment, given their higher barrier to resistance and antiviral activity across multiple HCV genotypes, characteristics that set them apart from other HCV drug classes. We look forward to reporting the first antiviral data with PSI-7851 in the second half of 2009."

About PSI-7851

PSI-7851 is a uridine nucleoside analog currently in developed for the treatment of chronic HCV infection. PSI-7851 has demonstrated in vitro anti-HCV activity with EC(50) values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than the active metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Like R7128, PSI-7851 has demonstrated in vitro activity against all of the most common HCV genotypes.

About Pharmasset'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , December 18, 2014 ... application/module that is used to store, manipulate, and ... comprises a patient tracking and scheduling system, result ... of RIS with HIS and other databases improves ... registration and patient scheduling, patient list management, radiology ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2ResMed To Announce Second Quarter 2015 Results 2
... demonstrated significant improvement in ADHD symptoms in adults, ... SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical company, today,presented ... in which VYVANSE,demonstrated significant improvements in Attention Deficit ... safety and efficacy,endpoints., "Adults with ADHD often ...
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
Cached Medicine Technology:Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3
(Date:12/21/2014)... In this report, the global powered surgical instruments ... application. The market, by power source, is segmented ... the market covers the handpieces; power source and ... further subdivided into drills, saws, reamers, staplers, vessel ... drivers, and others. Moreover, the power source and ...
(Date:12/21/2014)... Khanna Vision Institute is pleased to ... Aspen Helicopters holiday event for underprivileged kids. The highlight ... flown by an aspen helicopter pilot. In the cover ... sleigh was visible.(please see accompanying video). Helicopter pilots require ... helped many pilots with Pi in eye vision correction. ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. ... less addictive than traditional cigarettes, new research finds. ... regular cigarettes, thousands of ex-smokers said they have fewer cravings ... their need to smoke, researchers reported. "The ... for e-cig use than for tobacco use," said lead researcher ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage ... and the Doors International Ballroom at the Hilton Hotel ... the only time that Morrison's mother would see her ... 1967. According to Hawley, “This would be the Doors ... Alexandria Roller Rink earlier that year and would return ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... , THURSDAY, May 3 (HealthDay News) -- A ... with schizophrenia, cutting patients, risk of relapse by 60 percent. ... also found that schizophrenia patients who take antipsychotics are much ... and have a better quality of life than patients who ...
... jogging increases the life expectancy of men by 6.2 years ... the Copenhagen City Heart study presented at the EuroPRevent2012 meeting. ... hazardous, Peter Schnohr told delegates that the study,s most recent ... hours of jogging per week at a "slow or ...
... eating is motivated by pleasure, rather than hunger, endogenous rewarding ... to a recent study accepted for publication in The Endocrine ... The phenomenon ultimately affects body mass and may be a ... refers to the desire to eat for pleasure, and to ...
... New York, NYThe United States spends more on health care ... superior" care, according to a new study from The Commonwealth ... on health care services, while other countries in the study ... and Switzerland) as much. While the U.S. performs well on ...
... 2D mammography screening results in a 40% reduction in ... a new study shows., The study, conducted at Yale ... 7,578 screening mammograms, found that the recall rate was ... It was 11.1% for 2D screening mammography alone, ...
... with benign breast biopsies do not need follow-up at six months; ... shows. , The study, conducted at Moffitt ... and 24 months. No cancer was found in these patients ... the authors of the study. "Of the 197 follow-up examinations ...
Cached Medicine News:Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 2Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 3Health News:Regular jogging shows dramatic increase in life expectancy 2Health News:Regular jogging shows dramatic increase in life expectancy 3Health News:Pleasure eating triggers body's reward system and may stimulate overeating 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 3Health News:US spends far more for health care than 12 industrialized nations, but quality varies 4Health News:Digital breast tomosynthesis cuts recall rates by 40 percent 2